Movatterモバイル変換


[0]ホーム

URL:


Wayback Machine
50 captures
09 Jun 2013 - 23 Nov 2025
AugSEPOct
18
201620172018
success
fail
COLLECTED BY
Organization:Alexa Crawls
Starting in 1996,Alexa Internet has been donating their crawl data to the Internet Archive. Flowing in every day, these data are added to theWayback Machine after an embargo period.
Collection:Alexa Crawls
Starting in 1996,Alexa Internet has been donating their crawl data to the Internet Archive. Flowing in every day, these data are added to theWayback Machine after an embargo period.
TIMESTAMPS
loading
The Wayback Machine - https://web.archive.org/web/20170918070146/http://www.medscape.com:80/viewarticle/803884_6
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video New

Specialty:Multispecialty
Edition:ENGLISH
Log In
Sign Up It's Free!
Edition:ENGLISHDEUTSCHESPAÑOLFRANÇAISPORTUGUÊS
RegisterLog In

No Results

    No Results

      Medscape Logo
      Monday, September 18, 2017
      News & PerspectiveDrugs & DiseasesCME & EducationAcademyVideoNew
      close
      Please confirm that you would like to log out of Medscape.If you log out, you will be required to enter your username and password the next time you visit.Log outCancel
      Medscape Medical News from:

      This coverage is not sanctioned by, nor a part of, theAmerican Psychiatric Association.

      A Guide to DSM-5

      Bret S. Stetka, MD; Christoph U. Correll, MD

      Disclosures

      May 21, 2013

      In This Article

      Disruptive Mood Dysregulation Disorder (DMDD)

      The Change

      This new diagnostic category includes children exhibiting persistent irritability and severe behavioral outbursts 3 or more times per week for more than 1 year. The mood in between temper outbursts is persistently negative (irritable, angry, or sad), which is observable by others, and the tantrums and negative mood are present in at least 2 settings. To meet criteria for the new diagnosis, onset of illness has to be before age 10 years and in a child with a chronological or developmental age of at least 6 years.

      DMDD is intended to capture children with frequent temper tantrums and irritability, in part to prevent the overdiagnosis of bipolar disorder in youth with prepubertal onset of these symptoms. Often, such presentations result in a diagnosis of bipolar disorder or oppositional defiant disorder.[4]

      The Implications

      Critics of this update cite the modest body of research into the validity of DMDD as a viable diagnostic entity,[5] as well as the worry that such a diagnosis could increase the number of children diagnosed with mental illness and subsequent exposure to psychotropic medications with potential long-term side effects.

      Furthermore, a recent study by Axelson and colleagues[6] concluded that "In this clinical sample, DMDD could not be delimited from oppositional defiant disorder and conduct disorder, had limited diagnostic stability, and was not associated with current, future-onset, or parental history of mood or anxiety disorders. These findings raise concerns about the diagnostic utility of DMDD in clinical populations." In a follow-up editorial,[7] Dr. Axelson wrote, "One can conclude that at this time, not enough scientific data about these kids are available to create a new diagnosis. However, we should all agree on the vital importance of this problem and the need to expand our efforts to better understand the complex construct of irritability so that we can improve the assessment, diagnosis, and treatment of some of our sickest children."

      Although the validity and specificity of the new DMDD diagnosis remain in question, the hope is that the rise in bipolar disorder diagnoses for nonepisodic mood dysregulation and aggression with prepubertal onset may decrease. Whether this new diagnosis will also lead to a more judicious use of psychotropic medications and increased utilization of behavioral, psychosocial, and family interventions remains to be seen, but the addition of DMDD in DSM-5 will hopefully encourage such research.

        Medscape Psychiatry © 2013  WebMD, LLC

        Cite this article: Bret S. Stetka, Christoph U. Correll. A Guide to DSM-5 - Medscape - May 21, 2013.

        References
        Authors and Disclosures

        Authors and Disclosures

        Author(s)

        Bret S. Stetka, MD

        Editorial Director, Medscape Psychiatry & Mental Health

        Christoph U. Correll, MD

        Associate Professor of Psychiatry, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York; Medical Director, Recognition and Prevention Program, Zucker Hillside Hospital, Glen Oaks, New York

        Disclosure: Christoph U. Correll, MD, has disclosed the following relevant financial relationships:
        Served as a director, officer, partner, employee, advisor, consultant, or trustee for: Actelion Pharmaceuticals, Ltd; Alexza Pharmaceuticals; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc.; Desitin; Eli Lilly and Company; Gerson Lehrman Group; IntraCellular Therapies; Lundbeck, Inc.; Medavante; Medscape; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Otsuka Pharmaceutical Co., Ltd.; Pfizer; ProPhase; Sunovion; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA
        Served as a speaker or a member of a speakers bureau for: BMS; Merck; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Otsuka; Pfizer Inc
        Received research grant from: BMS; Feinstein Institute for Medical Research; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; National Institute of Mental Health (NIMH); National Alliance for Research in Schizophrenia and Depression; Otsuka Pharmaceutical Co., Ltd.
        Received income in an amount equal or greater than $250 from: Actelion Pharmaceuticals, Ltd; Alexza Pharmaceuticals; American Academy of Child and Adolescent Psychiatry; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Cephalon, Inc.; Eli Lilly and Company; Gerson Lehrman Group; GlaxoSmithKline; IntraCellular Therapies; Lundbeck, Inc.; Medavante; Medscape; Merck & Co., Inc.; National Institute of Mental Health; Novartis Pharmaceuticals Corporation; Ortho-McNeil-Janssen Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc; ProPhase; Sunovion; Takeda Pharmaceuticals North America, Inc.; Teva Pharmaceuticals USA

        Comments

        3090D553-9492-4563-8681-AD288FA52ACE

        Most PopularArticles

        According to PHYSICIANS
        1. The 6 Dietary Tips Patients Need to Hear From Their Clinicians
        2. Smartphones Hijack Cognitive Capacity
        3. Doctors and Depression: Suffering in Silence
        4. Saturated Fats and CVD: AHA Convicts, We Say Acquit
        5. Olive Oil Key Ingredient in Alzheimer's Prevention?
        View More
        My Alerts

        You have already selected for My Alerts

        Click the topic below to receive emails when new articles are available.

         

        You've successfully added to your alerts. You will receive email when new content is published.

        processing....

        What to Read Next on Medscape
        'legacyId= 803884chronicleID= 0901c791806034c1status= 2htmlStatus= 1gated= truesiteOn= 2001siteOnly= 2001suppressAds= falsesuppressMobile= falsetitle= A Guide to DSM-5contentTypeID= 10001contentGroupID= 0publicationID= 530publicationDate= 2013-05-20publicationName= Medscape PsychiatryleadTopic= 12leadConcept= 0leadConceptName= nullblockCode= Age.1_F06.30_F31_F33_F41_F42_F43_F84_gen.2languageCode= en_USactivityID= 0questionnaireID= 0publicationName= Medscape PsychiatrysectionTitle= nullsubsectionTitle= TestPubSubSectionsectionID= 0publication override tag= nullsection override tag= nullsubsection override tag= nullcollection id= 32841isCollection = truepublicationSuppressPrint= falseactivityID= 0activityExpirationDate= null'
        Medscape Consult
        Most Popular Articles
        According to PSYCHIATRISTS
        1. Olive Oil Key Ingredient in Alzheimer's Prevention?
        2. Smartphones Hijack Cognitive Capacity
        3. Probiotics Promising for Mild to Moderate Depression
        4. Inflammatory Dietary Pattern Linked to Brain Aging
        5. Exercise Top Lifestyle Factor for Alzheimer's Prevention?

        Recommendations

        b:curated curatedHasData : true
        Need a Curbside Consult?Share cases and questions with Physicians on Medscape Consult.Share a Case
        Email This
        Your Name is required.
        Subject is required.
        Please enter a Recipient Address and/or check the Send me a copy checkbox.
        Your email has been sent.
        is an Invalid Email Address.
        Medscape Logo

        Find Us On

        Group 2 34A8E98B-62ED-4216-98D6-E986304F4C2E

        About

        About MedscapePrivacy PolicyTerms of UseAdvertising PolicyHelp Center

        Membership

        Become a MemberEmail NewslettersManage My Account

        Apps

        MedscapeMedPulse NewsCME & Education

        WebMD Network

        WebMDMedicineNeteMedicineHealthRxListWebMD Corporate

        Editions

        EnglishDeutschEspañolFrançaisPortuguês
        All material on this website is protected by copyright, Copyright © 1994-2017 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
        This website uses cookies to deliver its services as described in ourCookie Policy. By using this website, you agree to the use of cookies.
        close
        MedscapeVideoNEWClinical. Captivating. Award-Winning. Explore Now

        [8]ページ先頭

        ©2009-2026 Movatter.jp